Physician profile
Sarah Fleming
NPI 1629586102
$7,667.54
in general payments reported to CMS, 2019-2025
60 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $777 · 2022: $1,345 · 2023: $1,610 · 2024: $1,563 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,545.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,039.74 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $958.33 | 2022-2025 | Piqray, Kisqali |
| Incyte Corporation | $431.44 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $275.95 | 2022-2025 | |
| Abbvie INC. | $269.62 | 2024-2025 | |
| Tg Therapeutics, INC. | $250.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.49 | 2021-2025 | Fruzaqla, Alunbrig, Vpriv |
| Genentech USA, INC. | $227.66 | 2024-2025 | Ocrevus, Tecentriq, Phesgo |
| Amgen INC. | $215.19 | 2022-2023 | Vectibix, Xgeva, Nplate |
| Glaxosmithkline, LLC. | $214.29 | 2023-2025 | Zejula, Jemperli |
| Daiichi Sankyo INC. | $209.98 | 2023-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $201.08 | 2021-2025 | Keytruda, Reblozyl, Lynparza |
| Astrazeneca Pharmaceuticals LP | $159.84 | 2021-2025 | Enhertu, Tagrisso |
| Jazz Pharmaceuticals INC. | $139.47 | 2021-2025 | |
| Tersera Therapeutics LLC | $132.41 | 2023-2025 | Zoladex |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $126.08 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.64 | 2022-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $118.39 | 2021-2023 | Epkinly, Imbruvica |
| Ipsen Biopharmaceuticals, INC | $115.57 | 2022-2025 | Tazverik, Onivyde, Somatuline Depot |
| Adaptive Biotechnologies Corporation | $113.33 | 2022-2025 | Clonoseq |
| Legend Biotech USA INC. | $111.06 | 2024-2025 | Carvykti |
| Pfizer INC. | $107.32 | 2022-2024 | |
| Sobi, INC | $104.21 | 2024-2025 | |
| Stemline Therapeutics INC. | $103.89 | 2025 | Orserdu |
| Eisai INC. | $96.63 | 2022-2023 | |
| Boston Scientific Corporation | $94.86 | 2024-2025 | Spaceoar Vue System - 10ml |
| Celgene Corporation | $86.81 | 2021-2023 | Reblozyl |
| Aspira Women'S Health INC | $80.00 | 2023 | Ova1 |
| Lilly USA, LLC | $73.36 | 2022-2023 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $73.06 | 2021-2025 | Xtandi |
| Array Biopharma INC | $71.24 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Servier Pharmaceuticals LLC | $70.37 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.11 | 2024-2025 | |
| Seagen INC. | $65.47 | 2021-2023 | Tivdak |
| Immunogen, INC. | $64.24 | 2023 | Elahere |
| Pharmacosmos Therapeutics INC. | $63.20 | 2023-2024 | Monoferric, Cosela |
| Myriad Genetic Laboratories, INC. | $62.90 | 2021-2023 | Precisetumor |
| Agios Pharmaceuticals, INC. | $62.52 | 2023-2025 | Pyrukynd |
| Coherus Oncology, INC. | $61.75 | 2023 | |
| Beigene USA, INC. | $60.23 | 2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $52.11 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $51.26 | 2021-2025 | Qinlock, Romvimza |
| G1 Therapeutics, INC. | $40.38 | 2023 | Cosela |
| Puma Biotechnology, INC. | $36.09 | 2025 | |
| Alexion Pharmaceuticals, INC. | $29.37 | 2023-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $28.23 | 2025 | Besremi |
| Exelixis INC. | $26.40 | 2025 | Cabometyx |
| Dova Pharmaceuticals | $24.93 | 2021 | |
| Iovance Biotherapeutics, INC. | $24.63 | 2025 | Amtagvi |
| Genmab U.S., INC. | $22.79 | 2024 | Epkinly |
| Karyopharm Therapeutics INC. | $22.45 | 2025 | Xpovio |
| Blueprint Medicines Corporation | $21.80 | 2024 | Ayvakit |
| Adc Therapeutics America, INC. | $21.71 | 2025 | |
| Delcath Systems | $21.26 | 2025 | Hepzato Kit |
| Dendreon Pharmaceuticals LLC | $20.47 | 2025 | Provenge |
| Beone Medicines USA, INC. | $18.11 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $16.74 | 2023 | Vonjo |
| Global Blood Therapeutics, INC. | $15.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2022 | |
| Recordati_rare_diseases_inc. | $13.28 | 2024 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.